Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
0
0
09/01/25
Dans
Amérique du Nord / États-Unis
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli Lilly's drug Zepbound, which could become a $100 billion market opportunity.
Montre plus
0 commentaires
sort Trier par
